Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series

BACKGROUND: Sarcomas are rare, heterogeneous tumors for which prognosis remains dismal in patients with advanced disease. Pazopanib, a vascular endothelial growth factor receptor inhibitor, has shown modest efficacy in patients with soft tissue sarcoma who fail cytotoxic chemotherapy. The cytotoxic...

Descripción completa

Detalles Bibliográficos
Autores principales: Bupathi, Manojkumar, Hays, John L., Chen, James L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687737/
https://www.ncbi.nlm.nih.gov/pubmed/29141017
http://dx.doi.org/10.1371/journal.pone.0188116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687737/
https://www.ncbi.nlm.nih.gov/pubmed/29141017
http://dx.doi.org/10.1371/journal.pone.0188116

Ejemplares similares